FXFeng Xie

Feng Xie

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Feng Xie has a total of 45 co-authors. Here are the top co-authors by number of shared publications:

  • Long Zhang

    Life Sciences Institute and State Key Laboratory of Transvascular Implantation Devices of the Second Affiliated Hospital of Zhejiang University School of Medicine, Zhejiang University, Hangzhou, China

    6 shared publications
  • Fangfang Zhou

    The First Affiliated Hospital of Soochow University, the Institutes of Biology and Medical Sciences, Suzhou Medical College, Soochow University, Suzhou, China

    5 shared publications
  • Xiaoxue Zhou

    School of Medicine, Hangzhou City University, Hangzhou, China

    3 shared publications
  • Shiyun Wan

    The First Affiliated Hospital, the Institutes of Biology and Medical Sciences, Suzhou Medical College, Soochow University, Suzhou, China

    2 shared publications
  • Alla Iansavichene

    London Health Sciences Center

    1 shared publication
  • Bing Yang

    Zhejiang University

    1 shared publication

Latest Publications

  • Open Access

    Spatial Proximity of LAG‐3 and T Cell Receptor: A New Paradigm for T Cell Suppression

    by Xiaoqi Miao, Xie Feng, Fangfang Zhou

  • Tumor–Immune Cell Interactions in Cancer Progression

    by Xiaoxue Zhou, Feng Xie, Long Zhang

    The tumor microenvironment is a complex ecosystem where immune cell components play a pivotal role in cancer progression. Aberrant immune responses within the tumor microenvironment are critical in tumor initiation, progression, metastasis, and prognosis, highlighting the urgent need to unravel tumor–immune interactions for improved therapies. This commentary reviews recent advancements in understanding tumor–immune interactions, focusing on both intrinsic factors, like cancer genetics and epigenetics, and extrinsic factors, such as metabolic reprogramming. We also examine key mechanisms of tumor–immune cross-talk, including exosome-mediated communication, liquid–liquid phase separation, and circulating tumor cells. Furthermore, we propose future research directions to improve strategies for combating cancer metastasis and enhancing therapeutic efficacy.


  • Open Access

    Bending and Scission: When the Membraneless Condensates Meet Endosome Membrane

    by Zhengkun Zhang, Feng Xie, Long Zhang

  • Top Cited Papers

    Targeting FOXM1 condensates reduces breast tumour growth and metastasis

    by Feng Xie, Xiaoxue Zhou, Yu Ran, Ran Li, Jing Zou, Shiyun Wan, Peng Su, Xuli Meng, Haiyan Yan, Huasong Lu, et al.

    Identifying phase-separated structures remains challenging, and effective intervention methods are currently lacking1. Here we screened for phase-separated proteins in breast tumour cells and identified forkhead (FKH) box protein M1 (FOXM1) as the most prominent candidate. Oncogenic FOXM1 underwent liquid–liquid phase separation (LLPS) with FKH consensus DNA element, and compartmentalized the transcription apparatus in the nucleus, thereby sustaining chromatin accessibility and super-enhancer landscapes crucial for tumour metastatic outgrowth. Screening an epigenetics compound library identified AMPK agonists as suppressors of FOXM1 condensation. AMPK phosphorylated FOXM1 in the intrinsically disordered region (IDR), perturbing condensates, reducing oncogenic transcription, accumulating double-stranded DNA to stimulate innate immune responses, and endowing discrete FOXM1 with the ability to activate immunogenicity-related gene expressions. By developing a genetic code-expansion orthogonal system, we demonstrated that a phosphoryl moiety at a specific IDR1 site causes electrostatic repulsion, thereby abolishing FOXM1 LLPS and aggregation. A peptide targeting IDR1 and carrying the AMPK-phosphorylated residue was designed to disrupt FOXM1 LLPS and was shown to inhibit tumour malignancy, rescue tumour immunogenicity and improve tumour immunotherapy. Together, these findings provide novel and in-depth insights on function and mechanism of FOXM1 and develop methodologies that hold promising implications in clinics.


  • Ketogenic diet and cancer: multidimensional exploration and research

    by Shiyun Wan, Xiaoxue Zhou, Feng Xie, Fangfang Zhou, Long Zhang

    The ketogenic diet (KD) has attracted attention in recent years for its potential anticancer effects. KD is a dietary structure of high fat, moderate protein, and extremely low carbohydrate content. Originally introduced as a treatment for epilepsy, KD has been widely applied in weight loss programs and the management of metabolic diseases. Previous studies have shown that KD can potentially inhibit the growth and spread of cancer by limiting energy supply to tumor cells, thereby inhibiting tumor angiogenesis, reducing oxidative stress in normal cells, and affecting cancer cell signaling and other processes. Moreover, KD has been shown to influence T-cell-mediated immune responses and inflammation by modulating the gut microbiota, enhance the efficacy of standard cancer treatments, and mitigate the complications of chemotherapy. However, controversies and uncertainties remain regarding the specific mechanisms and clinical effects of KD as an adjunctive therapy for cancer. Therefore, this review summarizes the existing research and explores the intricate relationships between KD and cancer treatment.


  • Top Cited Papers
    Open Access

    Mucosal immune response in biology, disease prevention and treatment

    by Xiaoxue Zhou, Yuchen Wu, Zhipeng Zhu, Chu Lu, Chunwu Zhang, Linghui Zeng, Feng Xie, Long Zhang, Fangfang Zhou

    The mucosal immune system, as the most extensive peripheral immune network, serves as the frontline defense against a myriad of microbial and dietary antigens. It is crucial in preventing pathogen invasion and establishing immune tolerance. A comprehensive understanding of mucosal immunity is essential for developing treatments that can effectively target diseases at their entry points, thereby minimizing the overall impact on the body. Despite its importance, our knowledge of mucosal immunity remains incomplete, necessitating further research. The outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has underscored the critical role of mucosal immunity in disease prevention and treatment. This systematic review focuses on the dynamic interactions between mucosa-associated lymphoid structures and related diseases. We delve into the basic structures and functions of these lymphoid tissues during disease processes and explore the intricate regulatory networks and mechanisms involved. Additionally, we summarize novel therapies and clinical research advances in the prevention of mucosal immunity-related diseases. The review also addresses the challenges in developing mucosal vaccines, which aim to induce specific immune responses while maintaining tolerance to non-pathogenic microbes. Innovative therapies, such as nanoparticle vaccines and inhalable antibodies, show promise in enhancing mucosal immunity and offer potential for improved disease prevention and treatment.


  • Open Access

    TRAF4 inhibits bladder cancer progression by promoting BMP/SMAD signalling pathway

    by Prasanna Vasudevan Iyengar, Dieuwke Louise Marvin, Dilraj Lama, Tuan Zea Tan, Sudha Suriyamurthy, Feng Xie, Maarten van Dinther, Hailiang Mei, Chandra Shekhar Verma, Long Zhang, et al.

    Bladder cancer is one of the most prevalent cancer types in the world, frequently exhibiting invasion and metastasis and therefore associated with poor prognosis. It is a progressive disease with high recurrence rates even after surgery, which calls for the urgent need for early intervention and diagnosis. The E3 ubiquitin ligase TNF Receptor Associated Factor 4 (TRAF4) has been largely implicated as a tumour-promoting element in a wide range of cancers. Over-expression and amplification of this gene product has been a common observation in breast and other metastatic tumours. In contrast, we observed that expression of TRAF4 negatively correlated with overall patient survival. Moreover, its expression was repressed at epigenetic levels in aggressive bladder cancer cells. We also describe an ERK kinase phosphorylation site on TRAF4 that inhibits its stability and localization to plasma membrane in such cells. Furthermore, knockdown of TRAF4 in epithelial bladder cancer cell lines leads to gain of mesenchymal genes and a loss of epithelial integrity. Reciprocally, stable over-expression of TRAF4 in mesenchymal cells leads to decreased migratory and invasive properties. Transcriptomic analysis upon TRAF4 mis-expression in bladder cancer cell lines revealed that higher TRAF4 expression enhanced BMP/SMAD and dampened NF-κB signalling pathways. Importantly, this notion was confirmed in bladder cancer patient material. Mechanistically, we showed that TRAF4 targets the E3 ubiquitin ligase SMURF1, a negative regulator of BMP/SMAD signalling, for proteasomal degradation in bladder cancer cells. We show that genetic and pharmacological inhibition of SMURF1 or its function inhibited migration of aggressive (mesenchymal) bladder cancer cells.